@entity7604 in the treatment of XXXX : a controlled trial.

@entity7604 @entity1 @entity712
This study examines the acute hemodynamic response to intravenous and oral @entity7604 in 12 @entity1 with moderate to moderately severe @entity712 . The @entity1 received @entity7604 or placebo at random in an 8-week double-blind trial. Dosing level and schedule were determined by the hemodynamic results. Acute and chronic plasma samples for @entity7604 concentration were drawn from @entity1 throughout the study. @entity7604 was administered intravenously in successive doses of 25, 50, and 75 micrograms/kg. This resulted in a 16.5%, 12.5%, and 28.4% peak increase in cardiac index, with a concomitant 24%, 29%, and 38% decrease in pulmonary capillary wedge pressure. There were no significant relationships between any of the mean maximal hemodynamic values and @entity7604 plasma concentration. Six @entity1 received @entity7604 and six @entity1 received placebo; only five @entity1 completed the blinded phase. There was no significant difference between the groups in exercise capacity, but the conditions of five of the six @entity1 who received placebo deteriorated. In two of the @entity1 who received @entity7604 the aerobic capacity improved greater than 2 cc/min/kg over baseline, and an additional two @entity1 reported a marked subjective improvement. The results of this study indicate that oral @entity7604 in the management of @entity1 with @entity712 would justify larger controlled studies.
